No Data
LifeSci Capital Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $80
Akero Therapeutics: Strong Financial Health and Promising Clinical Trial Results Drive Buy Rating
Akero Therapeutics | 8-K: Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Akero Therapeutics | 10-K: FY2024 Annual Report
Akero Therapeutics Reports Phase 2b SYMMETRY Study Results Demonstrating Significant Reversal of Compensated Cirrhosis and Updates on Phase 3 SYNCHRONY Program
Earnings Flash (AKRO) Akero Therapeutics Posts Q4 Total Operating Expenses $78M
throwing us a party at CYN soon. Everyone's invited. idk bout hamburgers but we'll be doing some grillin! 
